Profile data is unavailable for this security.
About the company
PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.
- Revenue in USD (TTM)0.00
- Net income in USD-82.71m
- Incorporated2013
- Employees63.00
- LocationPMV Pharmaceuticals Inc400 Alexander Park Drive, Suite 301PRINCETON 08540United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.pmvpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology Inc | 2.82m | -97.09m | 91.53m | 44.00 | -- | 1.33 | -- | 32.46 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Codexis Inc | 52.93m | -63.95m | 92.13m | 188.00 | -- | 2.39 | -- | 1.74 | -0.7514 | -0.7514 | 0.6238 | 0.4269 | 0.389 | 5.42 | 4.03 | 281,553.20 | -47.00 | -21.95 | -58.53 | -26.20 | 79.31 | 76.67 | -120.82 | -49.88 | 4.02 | -- | 0.5076 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 92.30m | 19.00 | -- | 4.72 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Ibio Inc | 300.00k | -24.74m | 92.92m | 20.00 | -- | 1.43 | -- | 309.74 | -1.26 | -1.26 | 0.0112 | 1.88 | 0.007 | -- | -- | 15,000.00 | -57.47 | -30.90 | -65.55 | -37.76 | -- | -- | -8,245.67 | -2,374.12 | -- | -- | 0.00 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 93.57m | 25.00 | -- | 2.56 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 93.89m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 80.84k | -14.68m | 94.47m | 12.00 | -- | -- | -- | 1,168.68 | -12.31 | -12.31 | 0.0563 | -3.64 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Citius Oncology Inc | 3.94m | -23.64m | 95.34m | -- | -- | 1.57 | -- | 24.17 | -0.3102 | -0.3102 | 0.0511 | 0.6889 | 0.0394 | 0.0426 | -- | -- | -23.58 | -- | -42.08 | -- | 79.99 | -- | -599.28 | -- | 0.3245 | -112.34 | 0.0611 | -- | -- | -- | -17.08 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 95.78m | 63.00 | -- | 0.7883 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 96.86m | 42.00 | -- | 5.22 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 97.01m | 56.00 | -- | 1.21 | -- | 510.56 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 98.80m | 4.00 | -- | 6.45 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 99.15m | 67.00 | -- | 3.15 | -- | 142.04 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 99.20m | 144.00 | -- | -- | -- | 2.25 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 104.23m | 23.00 | -- | 16.50 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
Data as of Mar 03 2026. Currency figures normalised to PMV Pharmaceuticals Inc's reporting currency: US Dollar USD
43.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2025 | 5.29m | 9.95% |
| Tang Capital Management LLCas of 31 Dec 2025 | 4.94m | 9.28% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2025 | 3.09m | 5.81% |
| Sio Capital Management LLCas of 31 Dec 2025 | 2.64m | 4.96% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 2.02m | 3.79% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.93m | 3.63% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 1.15m | 2.16% |
| Two Sigma Advisers LPas of 31 Dec 2025 | 874.10k | 1.64% |
| Two Sigma Investments LPas of 31 Dec 2025 | 706.06k | 1.33% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 703.96k | 1.32% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
